Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1156993 | 0.99 | CYP2E1 (0.39) | CYP2E1CYP3A4CYP2D6CYP2A6CYP2C9 | |
| Fumaric Acid SCHEMBL1278302 | 0.93 | CYP2E1 (0.37) | CYP2E1CYP3A4CYP2D6CYP2A6CYP2C9 | |
| Fumaric Acid SCHEMBL1278298 | 0.93 | CYP2E1 (0.37) | CYP2E1CYP3A4CYP2D6CYP2A6CYP2C9 | |
| SCHEMBL14300810 | 0.90 | CYP2E1 (0.39) | CYP2E1CYP3A4CYP2D6CYP2A6CYP2C9 | |
| SCHEMBL9988058 | 0.89 | CYP2C9 (0.40) | CYP2E1CYP3A4CYP2D6CYP2A6CYP2C9 | |
| SCHEMBL1580390 | 0.88 | TSHR (0.39) | MAPTTSHRPOLBEPHX2PRMT6 | |
| SCHEMBL1580769 | 0.87 | EPHX2 (0.34) | CYP3A4CYP2C9CYP2C19MAPTTSHR | |
| SCHEMBL29754033 | 0.87 | ALDH1A1 (0.39) | CYP3A4CYP2D6CYP2C19MAPTTSHR | |
| SCHEMBL194035 | 0.87 | ALDH1A1 (0.39) | CYP3A4CYP2D6CYP2C19MAPTTSHR | |
| Hydrochloric Acid SCHEMBL1156606 | 0.86 | ALDH1A1 (0.38) | CYP3A4CYP2D6CYP2C19MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143246-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | claimed |
| CN-110200903-B | Liquid formulations of amines and organic acids stabilized with salts | 武田药品工业株式会社 | 2022-07-29 | — | — | CN | claimed |
| EP-2866788-B1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-12-16 | — | — | EP | claimed |
| CN-110917130-A | Liquid formulations of amines and organic acids stabilized with salts | 武田药品工业株式会社 | 2020-03-27 | — | — | CN | claimed |
| US-20190070159-A1 | NOVEL PHARMACEUTICAL USES | TAKEDA PHARMACEUTICALS CO (JP) | 2019-03-07 | — | — | US | claimed |
| US-20180085361-A1 | NOVEL PHARMACEUTICAL USES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-29 | — | — | US | claimed |
| EP-2309985-B1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICALS CO (JP) | 2018-03-14 | — | — | EP | claimed |
| US-20150165027-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-18 | — | — | US | claimed |
| EP-2866788-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | Takeda Pharmaceutical Company Limited (JP) | 2015-05-06 | — | — | EP | claimed |
| EP-2327692-B9 | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2014-06-04 | — | — | EP | claimed |
| US-20110124687-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | claimed |
| EP-2309985-A2 | PHARMACEUTICAL COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2011-04-20 | — | — | EP | claimed |
| EP-1919865-B1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2011-04-06 | — | — | EP | claimed |
| WO-2010013823-A2 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-04 | — | — | WO | claimed |
| US-20090275591-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2009-11-05 | — | — | US | claimed |
| US-20090143444-A1 | ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-04 | — | — | US | claimed |
| US-7498337-B2 | Acid secretion inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-03 | — | — | US | claimed |
| EP-1919865-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2008-05-14 | — | — | EP | claimed |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | claimed |
| WO-2007026916-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143444-A1 | ACID SECRETION INHIBITOR | HRH2, VIP, CCKBR | CYP2E1 1786/4885CYP3A4 964/4885CYP2D6 2106/4885 |
| US-20110124687-A1 | PHARMACEUTICAL COMPOSITION | CYP2C19, MLST8, CYP3A43 | CYP2E1 1606/4885CYP3A4 57/4885CYP2D6 78/4885 |
| US-20150165027-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | OTC, SLC38A7, SRI | CYP2E1 1521/4885CYP3A4 405/4885CYP2D6 211/4885 |
| US-20090275591-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITOR | HRH2, ASNS, GHSR | CYP2E1 1077/4885CYP3A4 1244/4885CYP2D6 2024/4885 |
| US-20190070159-A1 | NOVEL PHARMACEUTICAL USES | ATP1A4, HRH2, ATP4A | CYP2E1 2779/4885CYP3A4 516/4885CYP2D6 623/4885 |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | HRH2, GIPR, HRH4 | CYP2E1 636/4885CYP3A4 980/4885CYP2D6 1880/4885 |
| US-20180085361-A1 | NOVEL PHARMACEUTICAL USES | ATP1A4, HRH2, ATP4A | CYP2E1 2779/4885CYP3A4 516/4885CYP2D6 623/4885 |
| US-20230143246-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | OTC, SLC38A7, SRI | CYP2E1 1521/4885CYP3A4 405/4885CYP2D6 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.